Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (111-120 of 323) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 21, 2016
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patientsAndrea Sartore-Bianchi, Filippo Pietrantonio, Alessio Amatu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Cancer Research and Treatment|November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-AnalysisChiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa TrialFilippo Pietrantonio, Federica Morano, Monica Niger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB TrialFilippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
Cell Metabolism|September 4, 2018
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesMaria Apicella, Elisa Giannoni, Stephany Fiore, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 29, 2023
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to actionLorenzo Fornaro, Sara Lonardi, Silvia Catanese, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studiesDaniele Rossini, Marco M Germani, Sara Lonardi, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 8, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancerLorenzo Castagnoli, Simona Corso, Alma Franceschini, et al.
Clinical Colorectal Cancer|March 9, 2019
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual InhibitionLorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, et al.
Pageof 33

Showing results (111-120 of 323) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|December 21, 2016
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patientsAndrea Sartore-Bianchi, Filippo Pietrantonio, Alessio Amatu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Cancer Research and Treatment|November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-AnalysisChiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa TrialFilippo Pietrantonio, Federica Morano, Monica Niger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB TrialFilippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
Cell Metabolism|September 4, 2018
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesMaria Apicella, Elisa Giannoni, Stephany Fiore, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 29, 2023
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to actionLorenzo Fornaro, Sara Lonardi, Silvia Catanese, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studiesDaniele Rossini, Marco M Germani, Sara Lonardi, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 8, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancerLorenzo Castagnoli, Simona Corso, Alma Franceschini, et al.
Clinical Colorectal Cancer|March 9, 2019
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual InhibitionLorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, et al.
Pageof 33